Status:
COMPLETED
Convalescent Plasma for Patients With COVID-19
Lead Sponsor:
Henry Ford Health System
Conditions:
Coronavirus Infection
Coronavirus
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.
Detailed Description
Importance: Convalescent plasma has been shown to be safe in patients with COVID-19, but whether it is clinically effective in patients with severe COVID-19 pneumonia is still unclear. Objective: To ...
Eligibility Criteria
Inclusion
- age \> 18 with one or more of the following: Dyspnea Respiratory rate \>= 30 breaths/min Oxygen saturation \<=93% PaO2/FiO2 \<300 Bilateral airspace opacities on chest radiograph at 24 to 48 hours
Exclusion
- Acute myocardial infarction in past 30 days Acute stroke in past 30 days VV ECMO VA ECMO
Key Trial Info
Start Date :
May 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04385199
Start Date
May 4 2020
End Date
August 1 2020
Last Update
May 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henry Ford Hospital
Detroit, Michigan, United States, 48202